Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Dosimetry models for radioimmunotherapy.

V K Langmuir1, R M Sutherland

  • 1University of Rochester Cancer Center, University of Rochester Medical Center, New York 14642.

Medical Physics
|November 1, 1988
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Shutdown of immunological priming and presentation after in vivo administration of adenovirus.

Gene therapy·2011
Same author

Without CD4 help, CD8 rejection of pig xenografts requires CD28 costimulation but not perforin killing.

Journal of immunology (Baltimore, Md. : 1950)·2001
Same author

Cell-associated ovalbumin is cross-presented much more efficiently than soluble ovalbumin in vivo.

Journal of immunology (Baltimore, Md. : 1950)·2001
Same author

Overcoming the poor immunogenicity of a protein by DNA immunization as a fusion construct.

Immunology and cell biology·2001
Same author

Delayed rejection of fetal pig pancreas in CD4 cell deficient mice was correlated with residual helper activity.

Xenotransplantation·2000
Same author

CD4 help-independent induction of cytotoxic CD8 cells to allogeneic P815 tumor cells is absolutely dependent on costimulation.

Journal of immunology (Baltimore, Md. : 1950)·2000
Same journal

Correction to "On the shape of the radiation survival curve in tumor spheroids: The role of oxygen heterogeneity".

Medical physics·2026
Same journal

Multi-view constrained semi-supervised vertebra detection for 3D ultrasound spine volume.

Medical physics·2026
Same journal

Accuracy of quantitative <sup>177</sup>Lu SPECT/CT imaging: A systematic review.

Medical physics·2026
Same journal

Physics-constrained dual-domain network for CBCT reconstruction from orthogonal X-rays in gynecologic radiotherapy.

Medical physics·2026
Same journal

Decomposition-based harmonization for quantitative PET imaging across scanners and radiotracers.

Medical physics·2026
Same journal

Development and evaluation of an in vivo dose-based monitoring system for electron FLASH radiation therapy.

Medical physics·2026
See all related articles

Tumor size impacts radiation dose from radiolabeled antibodies. Smaller tumors require higher concentrations, potentially favoring alpha-emitters for micrometastases, while larger tumors benefit from high-energy beta-emitters.

Area of Science:

  • Nuclear Medicine
  • Radiation Oncology
  • Medical Physics

Background:

  • Radiolabeled antibody therapy is crucial for cancer treatment.
  • Accurate absorbed dose determination is essential for efficacy and safety.
  • Non-uniform distribution of radiolabeled antibodies complicates dosimetry.

Purpose of the Study:

  • To evaluate how tumor size affects absorbed dose distribution from beta-emitters.
  • To analyze the impact of non-uniform radiolabeled antibody distribution on dose.
  • To compare dosimetry models for micrometastases and vascularized tumors.

Main Methods:

  • Development of two theoretical dosimetry models: one for nonvascularized micrometastases, one for vascularized tumors.
  • Assumption of no radionuclide penetration into the tumor.

Related Experiment Videos

  • Comparison of dose distributions with uniform radionuclide distribution.

    • Main Results:

    • In small micrometastases (<1 mm), low-energy emitters (e.g., 131I) yield higher dose rates due to reduced energy loss.
    • Therapeutic concentrations increase as tumor diameter decreases, potentially becoming unachievable in very small tumors (<0.5 mm).
    • In vascularized tumors, high-energy emitters (e.g., 90Y) provide higher doses and more even distribution due to overlapping sources.

    Conclusions:

    • Tumor size, antibody penetration, and vascularity are critical factors in selecting radionuclides for targeted therapy.
    • Alpha-emitters may be beneficial for micrometastatic disease, especially in combination with beta-emitters.
    • The choice of radionuclide (alpha, low-energy beta, high-energy beta, or combination) should be tailored to specific tumor characteristics.